This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
Company type | Private (family-owned) |
---|---|
Industry | Chemical, pharmaceutical |
Founded | 1927 |
Founder | Elio Bracco |
Headquarters | |
Area served | Worldwide |
Key people | Diana Bracco (President and CEO) |
Products | contrast agents, injectors, medical devices, pharma |
Revenue | €1,300,000,000 [1] |
Number of employees | 3400 (2015) |
Website | www |
The Bracco Group is an Italian multinational active in the healthcare sector with more than 3,300 employees worldwide, [2] which operates in a variety of business areas. [2]
Bracco has consolidated revenues of more than 1.1 billion euro, of which 75% from international sales. [3] The Group is present in 100 countries and invests approximately 10% of its core diagnostic imaging revenues in research and innovation. In Italy Bracco is also a brand associated with a number of historic pharmaceutical products such as Cebion, Xamamina, Euclorina, the Alfa eye-drops line and the Friliver range of sport supplements.
The Group Chairman and Chief Executive Officer is Diana Bracco. A chemistry graduate from the University of Pavia, Diana Bracco is also Chairman of Expo 2015 Spa, General Section Commissioner for the Italy Pavilion at Expo and Confindustria Vice President for Research & Innovation. Decorated as a Cavaliere del Lavoro, she was President of Assolombarda and, before that, Chairman of Federchimica. In February 2001 she received an Honorary Doctor of Pharmacy degree from University of Pavia. On January 12, 2015, Diana Bracco was "prosecuted on charges of tax evasion and embezzlement, crimes allegedly committed as chairman of the board of the pharmaceutical group Bracco Spa." [4] [5] [6] [7] In October 2016, she was given a two year suspended sentence for tax fraud and embezzlement. [8]
As of 2020, the group has a consolidated turnover of approximately 1.4 billion euros, of which 89% on foreign markets. It is present in 100 countries with 3,587 employees. [9] The Bracco group has 1,800 patents, 7 research and development centers and 9 factories worldwide. [10]
The company founded by Elio Bracco was established in 1927 in Milan with the name Società Italiana Prodotti E Merck, to produce, package and sell the chemical products of the German company E. Merck. It had just five employees. In 1934 Fulvio Bracco, Elio's son, officially joined the company which, the same year, began marketing Cebion, an innovative product based on vitamin C, recently discovered by the Hungarian biochemist Albert Szent-Györgyi. In 1962 Bracco researchers created the first contrast agent based on their original research: iodamide, a product with very high tolerability. On 17 March 1977 Diana Bracco, Fulvio's daughter, was appointed Bracco General Manager.
In 1981 the company launched Iopamidol in Italy and Germany. In the second half of the 1980s, Bracco Spa became the leading international producer of non-ionic contrast agents. It also won a positive response and important results for other formulations, including the anti-tuberculosis drug pyrazinamide, of which Bracco is the leading world producer, which is included in the WHO list of essential pharmaceuticals.[ citation needed ]
In 1990, Bracco began a ten-year period of important growth. At international level, acquisitions and joint ventures enhanced the Group structure. In 1990 the Bracco Eisai joint venture was set up in Japan. In 1994 Bracco acquired Squibb Diagnostic, a company in the Bristol Myers Squibb group in the United States, which is still Bracco Imaging's largest market today. 1995 saw the integration of the three research centres in Milan, Geneva and Princeton: Milan focuses on the research and development of contrast agents for radiology and magnetic resonance, Bracco Research Geneva on ultrasound and Bracco Research USA Princeton on magnetic resonance and nuclear medicine.
1999 was a milestone year for the company: the Bracco family and the Merck Group reached an agreement under which Bracco bought Merck's 50% stake in the Group's diagnostic and pharmaceuticals operations. In 2001, the Bracco Group acquired ACIST Medical Systems, a US company based in Eden Prairie, Minnesota, a suburb of Minneapolis, active in advanced contrast-agent management and injection systems. Meanwhile, the Group's international growth continued, with more offices opening around the world. Since 2002 Bracco has had a direct presence in China with Bracco Sine Pharmaceutical Corp. Ltd. in Shanghai. In 2008 it acquired E-Z-EM, a leading company in the radiology sector. In 2010 Bracco entered Estonia, Scandinavia and South Korea. In 2011 Bracco Imaging acquired Swiss Medical Care (now Bracco Injeneering) and the Nycomed production plants in Singen (Germany). In 2012 it completed the acquisitions of Justesa in Argentina, Mexico and Brazil.
Pharmaceutical Research and Manufacturers of America, formerly known as the Pharmaceutical Manufacturers Association, is a trade group representing companies in the pharmaceutical industry in the United States. Founded in 1958, PhRMA lobbies on behalf of pharmaceutical companies. PhRMA is headquartered in Washington, D.C.
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.
GE HealthCare Technologies, Inc., organized in Delaware and headquartered in Chicago, Illinois, focuses on health technology. The company operates 4 divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures contrast agents and radiopharmaceuticals.
ItAli Airlines S.p.A. was an airline based in Rome. It operated regional scheduled, charter and cargo services, as well as air taxi flights. Its main base was Leonardo da Vinci-Fiumicino International Airport, Rome.
Zonisamide, sold under the brand name Zonegran among others, is a medication used to treat the symptoms of epilepsy and Parkinson's disease. Chemically it is a sulfonamide. It serves as an anticonvulsant used primarily as an adjunctive therapy in adults with Parkinson's disease, partial-onset seizures; infantile spasm, mixed seizure types of Lennox–Gastaut syndrome, myoclonic and generalized tonic clonic seizure. Despite this it is also sometimes used as a monotherapy for partial-onset seizures.
Renato Soru is an Italian politician and entrepreneur. He is the founder of the internet service company Tiscali, based in Cagliari. Forbes listed Soru as one of the world's richest people, with a net worth of over $4 billion as of September 2001.
Sigma-Aldrich is an American chemical, life science, and biotechnology company owned by the multinational chemical conglomerate Merck Group
The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth US$110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.
Zambon is an Italian company that has been operating in the pharmaceutical and fine chemical industry since 1906. The company is currently run by Elena Zambon who is the daughter of the founder.
Eribulin, sold under the brand name Halaven among others, is an anti-cancer medication used to treat breast cancer and liposarcoma.
Curia is a contract research and manufacturing organization that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries. Founded in 1991, Curia operates in the United States, Europe and Asia, with its headquarters located in Albany, New York. Curia has announced deals and collaborations with such companies as Pfizer Inc., Merck & Co., Eli Lilly and Company, Takeda, Genentech, Bristol-Myers Squibb Co. and GE.
The Piramal Group is an Indian multinational conglomerate that has presence across various sectors such as healthcare, life sciences, drug discovery, financial services, alternative investment and real estate.
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries.
The Global Health Innovative Technology Fund, headquartered in Japan, is an international public-private partnership between the Government of Japan, 16 pharmaceutical and diagnostics companies, the Bill & Melinda Gates Foundation, the Wellcome Trust and United Nations Development Programme. It funds scientific research and development for anti-infectives and diagnostics for diseases that primarily affect the developing world. Bill Gates has noted that "GHIT draws on the immense innovation capacity of Japan’s pharmaceutical companies, universities and research institutions to accelerate the creation of new vaccines, drugs and diagnostic tools for global health." Margaret Chan, former Director-General of the World Health Organization, said: "The GHIT Fund has stepped in to provide that incentive in a pioneering model of partnership that brings Japanese innovation, investment and leadership to the global fight against infectious disease."
The Cathay Drug Company, Inc. (CDCI) is a Philippine pharmaceutical company based in Makati.
Esaote SpA is an Italian company operating in the biomedical sector that deals with the design, production, sale and maintenance of equipment for medical diagnostics.
Romano Volta is an Italian businessman who is the executive chairman and founder of Datalogic, an Italian company manufacturing barcode readers, mobile computers, radio-frequency identification, sensors for detection, and other electronic equipment.
Gadopiclenol, sold under the brand name Elucirem among others, is a contrast agent used with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and in the body. Gadopiclenol is a paramagnetic macrocyclic non-ionic complex of gadolinium.